Document is current
Any future updates will be listed below
-
Authors
Toner-Bartelds, Catherine
Mimpen, Iris L.
Parra-Martinez, Miguel
Burgering, Boudewijn M. T. https://orcid.org/0000-0002-4044-9596
Voest, Emile E. https://orcid.org/0000-0001-8249-9586
-
Funding
Funding for this research was provided by:
AvL Foundation Oncode
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 28 March 2026
First Online: 21 April 2026
Competing interests
: E. Voest is the founder and current member of the supervisory board of the Hartwig Medical Foundation, an independent non-executive director and shareholder of Sanofi, a co-founder and shareholder of Mosaic Therapeutics, and a board member and founder of the Centre for Personalised Cancer Treatment. He has received clinical study grants from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Clovis, Eisai, Eli Lilly, GSK, Ipsen, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, Servier, Incyte, MRM Health and Sanofi, all paid to the Netherlands Cancer Institute. C. Toner-Bartelds, I. Mimpen, M. Parra-Martinez and B. Burgering declare no competing interests.
